LABU250117P225000
- 0.00
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Analyst Expectations For Amgen's Future
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
This Is What Whales Are Betting On Amgen
Intellia Downgraded at Morgan Stanley on Lowered Expectations for Rare Disease Asset
Amgen Analyst Ratings
Allurion Stock Soars 70% on Weight-loss Therapy Update
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Crinetics Upgraded to Buy by Jefferies, Atumelnant Potential Cited
Natera Shares Are Trading Higher After the Company Announced It Will Reveal New Insights and Innovations for Tissue-free MRD at ASCO GI 2025
Neurocrine Announced Publication Of Supplement On Classic Congenital Adrenal Hyperplasia In The Journal Of Clinical Endocrinology & Metabolism, Covering Clinical, Psychosocial, Treatment Challenge
Alnylam Pharmaceuticals Analyst Ratings
8 Health Care Stocks Whale Activity In Today's Session
Looking Into Natera's Recent Short Interest
Argenx Cut to Sell at Deutsche Bank on Valuation
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation
The End Of The 60/40 Portfolio
Nvidia To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Friday
'Ozempic Is In The Next Round Of Medicare Drug Price Negotiations. See The Full List Of 15 Medications' - CNBC
Amgen Announced FDA Approval Of LUMAKRAS Combined With Vectibix For KRAS G12C-Mutated Metastatic Colorectal Cancer; Phase 3 CodeBreaK 300 Study Showed More Than Doubled Progression-Free Survival (5.6 Months) Compared To SOC (2 Months); Primary...
Natera Analyst Ratings